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Problem
Methods to limit fertility of feral swine are needed to reduce transmission of diseases and agricultural and ecosystem damage.
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Method of Study
We evaluated a single-shot GnRH immunocontraceptive vaccine in both
male and female feral swine for its effect on fertility and functional status of the reproductive tissues. Captive feral pigs were randomly
assigned to receive 1000 or 2000 lg GnRH-KLH vaccine treatments or
no treatment.
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Results
After 36 weeks, none of the 2000-lg-treated females and only 20% of
the 1000-lg-treated females were pregnant. This corresponded to
reduced serum progesterone, regressed tissues within the reproductive
tract and lack of evidence for follicular development leading to ovulation. Males were less responsive to the vaccine than females, but more
responsive to the lower dose of the vaccine than the higher dose.

doi:10.1111/j.1600-0897.2006.00379.x

Conclusions
The single-shot GnRH vaccine is effective in controlling fertility of
female feral swine and may be useful for population reduction.

Introduction
Populations of feral swine (Sus scrofa) have been
reported for 23 states with the total population estimated to be 3 million animals.1,2 Although recreational hunting of feral swine is popular in in some
states, overabundance of feral swine is a problem
that raises concerns relating to ecosystem and agricultural damage, and of disease threat to wildlife,
domestic livestock and humans.
Feral swine are known reservoirs for both brucellosis and pseudorabies. Swine brucellosis is caused
by the bacterium Brucella suis and is characterized by
abortion, infertility, lameness, and vulval discharges
in infected animals.3 The afterbirth of Brucella-infec-

ted pigs may also transmit the disease to cattle.4,5
Humans are also susceptible to swine brucellosis,
putting persons who come in contact with feral
swine at risk. Pseudorabies is a highly contagious
herpes viral disease which occurs in swine. The virulence of the feral swine pseudorabies strain is considerably less than that of the strain isolated from
domestic pigs.2 However, once swine are infected
with the virus they will remain infected for the rest
of their lives, although they may not show clinical
signs of the disease. Swine infected with pseudorabies are capable of transmitting the disease to other
species including cattle, sheep, goats, horses, dogs,
and cats. Pseudorabies infections in these secondary
species are usually fatal.
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Control of fertility of overabundant wildlife and
feral species is a topic that has received considerable
attention in recent years.6 Immunocontraceptive vaccines have been the focus of much infertility research
with the goal of population management being a single-dose, long-acting contraceptive that is highly
effective with minimal adverse effects. Research on
an immunocontraceptive vaccine of particular interest for swine targets gonadotropin-releasing hormone
(GnRH). Several short-term investigations have studied GnRH vaccines for commercial swine production
with an interest in using the approach as an alternative to surgical castration of boars.7–9 The GnRH
vaccine stimulates antibody production to inactivate
endogenous GnRH, and thereby reduces release of
gonadotrophic hormones leading to gonadal atrophy.10 As a result, regression or lack of development
of the reproductive organs results in ‘immunological
castration’. Although evidence from other species
suggests that the vaccine is effective in both males
and females, and produces both infertility and cessation of sexual activity, studies with swine have
primarily focused on evaluating the effects of the
vaccine in males. Recently, however, we demonstrated that a single-shot GnRH vaccine developed at the
National Wildlife Research Center, USDA-APHIS was
80–90% effective in preventing estrus behavior and
pregnancy in domestic pigs.11
Evidence suggests that among feral swine, oral
contact with reproductive discharges and sexual
activity are the primary means of transmission of
both brucellosis4 and pseudorabies.12 Our interest in
evaluation of a GnRH immunocontraceptive vaccine
for feral swine is based on recent studies with deer
and domestic pigs in which we demonstrated that
both fertility and reproductive behavior are greatly
diminished.11,13 We believe that the GnRH vaccine
represents a potentially ideal contraceptive vaccine
for feral swine because it induces infertility in both
sexes and limits the spread of brucellosis and pseudorabies by limiting sexual activity.
Although we have demonstrated the effectiveness
of our GnRH vaccine in domestic swine,11 we were
also interested in establishing the efficacy of the vaccine in a mixed feral population of different size
males and females, including pregnant, non-pregnant and breeding animals, as this is more typical of
what would be encountered in the field. Therefore,
the present study was undertaken to evaluate a single-shot GnRH vaccine in both male and female feral
swine for its effect on fertility and status of the

reproductive tissues. This effort represents the first
step in developing a strategy to use the vaccine to
limit fertility and reproductive behavior as a means
to reducing the transmission of brucellosis and pseudorabies among feral swine.
Materials and Methods
Male and female feral swine of unknown history
were captured throughout Florida in January–March
of 2002. The animals were brought to a farm near
Trenton, Florida where they were tested for pseudorabies and brucellosis and dewormed. Animals which
tested positive for brucellosis and pseudorabies
were not used in the study. Some of the female pigs
were pregnant when they were captured. Although
the weights of the animals were not taken, the range
was estimated to be 7–32 kg. Pigs were maintained
for the entire study in outdoor pens located in a
shaded, sandy area. The study was approved by the
Institutional Animal Care and Use Committee of the
Pennsylvania State University.
The GnRH vaccine and adjuvant used were developed at the National Wildlife Research Center and
were previously evaluated in white-tailed deer.13 The
vaccine consisted of the GnRH peptide conjugated to
keyhole limpet hemocyanin used in combination
with AdjuVacTM adjuvant (National Wildlife Research
Center, USDA-APHIS, Ft. Collins, CO, USA). The
adjuvant contained a modified Johne’s vaccine,
MycoparTM (Ft. Dodge Animal Health, Overland Park,
KS, USA), as a replacement for Freund’s adjuvant.
Male and female pigs were randomly assigned to
1000- or 2000-lg GnRH-KLH vaccine treatment or
no treatment. Eleven females received the 1000-lg
dose, nine females received the 2000-lg dose and
five females were untreated. Ten males received the
1000-lg dose, 10 males received the 2000-lg dose
and four males were untreated.
At the beginning of the study, blood samples were
taken and the pigs were immunized with the GnRH
vaccine by an intramuscular injection in the rump.
Males and females were separated, and large and
small pigs of each sex were further sorted into separate pens. Approximately 12 weeks after immunization, blood samples were taken and both treated and
untreated males and females were combined
together into two large breeding pens where they
remained for the duration of the study. Each pen
contained both treated and untreated males and
female for the remainder of the study. Although
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Results
Antibody titers for GnRH were negative in preimmunization samples and in all samples taken from
untreated pigs. For males, antibody titers were greatest 12 weeks after immunization with either the
1000- or 2000-lg dose vaccine (Fig. 1), although titers for both doses declined after 36 weeks. Values for
males receiving the 1000-lg dose were greater than
those receiving the 2000-lg dose at both time points,
but were only significant at 36 weeks. In contrast,
females receiving either the 1000- or 2000-lg dose
had similar titers at 12 weeks, but those receiving the
2000-lg dose significantly greater titers at 36 weeks
than those receiving 1000 lg of GnRH (Fig. 1).

GnRH titer (× 1000)

140
120
100
80
60
40
20
0
1000 µg
male

2000 µg
male

1000 µg
female

2000 µg
female

Fig. 1 Serum antibody titers at 12 weeks (open bars) and 36 weeks
(solid bars) post-immunization of male (n ¼ 10) and female (n ¼ 9)
feral pigs receiving a single intramuscular injection of either a 1000 or
2000 lg dose of GnRH vaccine. Data are not shown for serum titers
of untreated pigs (n ¼ 5), which were all negative.

Average serum progesterone concentrations for all
females were £6 lg/ml at the initial bleed and
12 weeks thereafter. After 36 weeks, average serum
progesterone concentrations were also <6 lg/ml for
the treated females, and were significantly less than
untreated females which averaged 32 lg/ml of progesterone at 36 weeks. Progesterone values for
untreated females corresponded with the percentage
of females within each treatment group having corpora lutea in ovaries collected at the end of the
study (Fig. 2). Treated females had considerably
fewer corpora lutea than control females.
Average serum testosterone concentrations were
similar for all groups of males at the start of the
study. However, serum testosterone concentrations
were significantly less than those of untreated males
120

Females with Corpera lutea (%)

there was no designated observation period, breeding activity was recorded if it was observed. Sows
giving birth during the study were noted, as was the
pregnancy status of the females at the end of
the study. During the study, two females assigned to
the 1000-lg treatment and one male assigned to the
2000-lg treatment died. In addition, two females
and one male in the control groups died. There was
no evidence that the deaths were related to the
treatments.
In mid-December, 36 weeks after immunization,
pigs were killed, a blood sample was taken and the
ovaries and testes were recovered. The gonads were
weighed and a sample of tissue was fixed in 10%
formalin-Ca++ and later prepared for histological
evaluation. For a few animals in each treatment, tissue samples of uterus, oviduct, and epididymis were
also collected for histological evaluation. Blood samples were used to assay antibody titers for GnRH and
testosterone and progesterone.
Histological evaluations were made on coded
slides. In males, the testis was evaluated for the presence of cell types associated with spermatogenesis
including spermatogonia, primary spermatocytes,
round spermatids and elongated spermatids. The
functional state of the Leydig cells and the presence
of spermatozoa in the epididymis were also considered. For females, the ovaries were examined for stages of follicular development and presence of corpora
lutea. Uterus and oviduct samples were examined to
determine whether the epithelia lining the uterine
and oviduct lumen were active or regressed.
Differences among treated and untreated groups
were assessed by least significant difference tests14
for multiple comparisons at P < 0.05.
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Fig. 2 Percentage of females with ovaries containing corpora lutea in
the untreated (n ¼ 3), 1000 lg (n ¼ 9) and 2000 lg (n ¼ 8) treatment
groups.
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Fig. 3 Plasma testosterone concentrations at the start of the study
(striped bars) and at 12 weeks (solid bars) and 36 weeks (open bars)
post-immunization. For the 1000 lg, n ¼ 10 for each time point. For
the 2000-lg group n ¼ 8 at the initial and 12 week samples and 7 at
the 36-week sampling. For the untreated males, n ¼ 4 for the initial
sample and n ¼ 3 for the 12- and 36-week samplings. Error bars are
mean ± standard error.
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matocytes. Four of 10 males (40%) in the 1000-lg
treatment had evidence of a negative effect on
round and elongated spermatids, and reduced sperm
in the epididymis. However, in the 2000-lg group,
no males showed a negative impact on round spermatids or epididymal sperm, and only two of seven
males (29%) had a negative effect on elongated
spermatids. These observations are consistent with
the conclusion that the lower vaccine dose was more
effective in interfering with spermatogenesis than
the higher vaccine dose.
Ovarian tissue from untreated females contained
primary and tertiary follicles and evidence of recent
corpora lutea. Although all females in both treated
groups showed evidence of follicular development
through the tertiary stage, the majority of these
females in both treated groups (70% and 67%,
respectively) lacked evidence of recent corpora lutea,
indicating an absence of recent ovulations (Fig. 2).
Although uterine tissue was not recovered from all
treated animals, three of five samples recovered from
the 1000-lg-treated females (60%) and seven of
nine samples from the 2000-lg-treated females
(78%) had evidence of regressed uterine epithelia.
These observations are consistent with the reduced
fertility and the regressed reproductive tracts of the
treated females.
Pregnancy status was noted during the study and
at slaughter (Fig. 5). All untreated females gave birth

10

at both 12 and 36 weeks for males receiving either
1000 or 2000 lg of GnRH (Fig. 3). However, testis
weight at 36 weeks was only significantly lower in
males receiving the 1000-lg dose (Fig. 4).
Testis tissue from untreated males contained all
cell types associated with normal spermatogenesis.
In the 1000-lg group, Leydig cells were regressed in
four of the 10 males examined, while only two of
eight males examined in the 2000-lg group had
regressed Leydig cells. No males in the 2000-lg
group and only three of 10 males (30%) in the
1000-lg showed a negative effect on primary sper-
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Fig. 4 Testis weights at 36 weeks post-immunization for untreated
(n ¼ 3), 1000 lg (n ¼ 10) and 2000 lg (n ¼ 7) treated boars. Error
bars are mean ± standard error.
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Fig. 5 Percentage females pregnant in untreated (n ¼ 3) and 1000 lg
(n ¼ 9) and 2000 lg (n ¼ 9) treated groups during the study (open
bars), and at the conclusion of the study (closed bars).
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sometime during the course of the study (n ¼ 5),
and all surviving swine were pregnant at slaughter
(n ¼ 3). In contrast, only 56% and 10% of the
females gave birth during the study in the 1000-lg
(n ¼ 9) and 2000-lg (n ¼ 9) treated groups, respectively. Moreover, at slaughter, only 11% of the
females receiving the 1000-lg dose (n ¼ 9) were
pregnant and none of the females receiving the
2000-lg dose (n ¼ 9) were pregnant.
Discussion
GnRH vaccines have been under development and
of primary interest for use in several domestic species, including cattle, horses, sheep, as well as
swine.15 Males have been the primary focus of these
studies with an interest in developing a vaccine capable of immunological castration. GnRH vaccines
that produce adequate antibody titers are believed to
act on the hypothalamus and inhibit synthesis and
secretion of GnRH which normally stimulates production of follicle stimulating hormone and luteinizing hormone by the anterior pituitary gland. In the
absence of these hormones, normal stimulation of
the testes and ovaries is compromised and gonadal
regression occurs. In the present study, a singleinjection GnRH-KLH vaccine combined with AdjuVac adjuvant was effective in producing antibody titers that were sufficient to impact several aspects of
reproduction in both male and female feral pigs.
In males, the effects included reduced testis
weight, reduced plasma testosterone and some histological evidence for effects on spermatogenesis and
Leydig cell regression. However, the histochemical
analyses suggested that spermatogenesis was disrupted in only a few males as a result of the treatment.
A limitation of this study was that it was not possible
to actually measure the fertility of individual males,
making it difficult to assess the true effect of the vaccine with respect to contraception. In addition, the
36-week study may not have been adequate to
assess the full effect of antibody titers on spermatogenesis.
An unexpected result was that the negative effect
of the vaccine appeared to be greater in males given
the lower 1000-lg dose than that of the 2000-lg
dose during the entire 36-week study. Although difficult to explain, this observation was consistent for
all end points measured and was clearly associated
with greater antibody titers for males receiving the
1000-lg dose. Higher titers were associated with

greater physiological effects, but not with greater
vaccine dose. Under the conditions of this study, it
does not appear that either of the GnRH vaccine
doses had a clear negative effect on the reproductive
physiology of male feral swine. These observations
may justify evaluation of additional vaccine doses
for males below 1000 lg, or between 1000 and
2000 lg to determine if greater antibody titers and
physiological effects can be achieved than were
observed in this study.
In contrast to the observations made for males,
the GnRH vaccine was highly effective for contraception of females. Contraceptive effects of the singleshot vaccine prevented pregnancy after 36 weeks in
all the females receiving the 2000-lg dose, and in
80% of the females receiving the 1000-lg dose. During the study, only one female receiving the higherdose vaccine produced offspring, while 55% of the
females receiving the lower dose had piglets during
the 36-week study. Differences observed between
the two treatments appear to be related to antiGnRH titers present at slaughter. It is noteworthy
that while titers were similar between both treatments 12 weeks after immunization, the higher titer
was better sustained after 36 weeks in females
receiving the 2000-lg dose.
Because the pregnancy status of the females during the course of the study could only be determined
for those that farrowed or were obviously pregnant,
it is not possible to know with certainty the mechanism of the anti-fertility effect. Relative to controls,
the percentage of females with corpora lutea was
considerably less in the treated groups suggesting
that fewer ovulations occurred in the treated females
leading to a negative effect on fertility. However, as
approximately 30% of the treated females had evidence of recent ovulations at slaughter, and only
22% (1000 lg) and 0% (2000 lg) of the treated
females were pregnant at slaughter it is possible that
the infertility effect was the result of early embryonic mortality or abortion.
An intriguing observation related to the vaccine
doses was that males responded better to the lower
dose than the higher vaccine dose, contrary to what
was observed for females. Gender differences do
exist in the pattern of GnRH and gonadotropic hormone secretion. Non-pregnant females typically
have a cyclic pattern of hormone secretion related to
the estrous cycle in contrast to males that secrete
GnRH at a relatively constant rate. Although the
absolute titers of males and females were similar at
American Journal of Reproductive Immunology 55 (2006) 378–384 ª 2006 The Authors
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12 weeks, titers of males appeared to decline at
36 weeks while those of females appeared to
increase. It is possible that the cyclic pattern of hormone secretion in females served as a periodic ‘selfboosting’ immunization, resulting in a greater ability
to sustain an immune response over time. In addition, with a steady pattern of GnRH secretion in
males, it is possible that circulating levels of GnRH
antibodies could have been reduced through the formation of antibody-GnRH complexes. Another difference between male and female gamete physiology
is that over the period of the female reproductive
cycle, 10–20 oocytes are ovulated, whereas in males,
literally billions of sperm are produced. These relative differences in the number of gametes produced
clearly suggest that the challenge to eliminate or
interfere with sperm production is far greater than
that for oocyte production.
Evaluation of the injectable single-shot GnRH vaccine in feral swine has shown it to be highly effective in reducing fertility of females for the 36-week
study. These observations agree with results obtained
with the single-shot GnRH vaccine used on domestic
gilts.11 In contrast to the study with domestic gilts,
however, the feral females treated were comprised
of a mixed population of sows and gilts of different
sizes and pregnancy status. These findings indicate
that the anti-fertility effects of the GnRH vaccine
would be broadly effective for treating diverse populations of feral females encountered in the field.
Although the vaccine gave less impressive results in
males, in practical terms these finding are encouraging because females are the likely target of contraceptive use in the field. An additional beneficial
effect of GnRH vaccine use in the field would be the
reduction of mating behavior, which would serve to
reduce venereal transmission of pseudorabies and
brucellosis among feral swine. Because an injectable
form of a contraceptive vaccine will have only limited field application for feral swine, emphasis and
resources in future research will be directed toward
further development of this GnRH vaccine into a
form for oral delivery.
Conclusions
The single-shot GnRH immunocontraceptive vaccine
was effective in reducing fertility of a mixed population of male and female feral swine and may be useful for contraception and disease control of feral
populations.
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